Quanterix Announces Q3 2024 Financial Results Call Scheduled for November 12

Quanterix Prepares for Q3 2024 Financial Results Call

Quanterix Corporation, a leader in ultrasensitive biomarker detection based in Billerica, Massachusetts, announces a forthcoming conference call set for November 12, 2024, at 4:30 p.m. E.T. The call aims to discuss the company's financial outcomes for the third quarter of 2024. Prior to the call, Quanterix will issue a press release detailing these results after the market closes, providing stakeholders with in-depth insights into the company's performance. The call will be accessible through a dedicated dial-in number and a live webcast on the Quanterix website, ensuring transparency and engagement with investors and analysts alike.

As a pioneer in the field of biomarker detection, Quanterix utilizes its proprietary Simoa® technology to achieve unparalleled sensitivity in measuring proteins found in blood, serum, or plasma. This innovative approach sets a new standard in the biomarker detection landscape, enabling researchers and clinicians to gain deeper insights into various medical conditions. The company’s digital immunoassay technology and its CLIA-certified Accelerator laboratory play pivotal roles in advancing research across multiple disciplines, including neurology, oncology, immunology, cardiology, and infectious diseases. By enabling more precise measurements of biomarkers, Quanterix significantly contributes to the evolution of personalized medicine and targeted therapies.

Quanterix has established a strong presence in the scientific community, with its research featured in over 3,100 peer-reviewed journals over the past two decades. This extensive body of work underlines the company's commitment to innovation and excellence, reinforcing its reputation as a trusted partner for researchers and healthcare professionals. As the company looks ahead to its upcoming financial results call, it continues to embrace forward-looking statements that reflect its expectations while acknowledging the inherent risks and uncertainties that accompany such forecasts. This proactive communication strategy aligns with Quanterix's dedication to fostering transparency and engagement with its stakeholders.

In addition to the financial results call, Quanterix encourages interested individuals to explore further details on its technological advancements and research contributions by visiting their website or following their social media channels on Twitter and LinkedIn. The company’s commitment to advancing healthcare through innovative biomarker detection remains a focal point of its operational strategy, promising continued growth and significant contributions to the medical field.